Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropsychiatr Dis Treat ; 20: 877-884, 2024.
Article in English | MEDLINE | ID: mdl-38645712

ABSTRACT

Background: Subjective social status influences anxiety, but at present, the mechanism is not fully understood. It has been reported that negative childhood experiences, such as abuse, can influence depressive symptoms through subjective social status and personality traits, such as self-esteem. A similar mechanism is presumed to underlie anxiety symptoms in adulthood. Therefore, we hypothesized that subjective social status and self-esteem are intermediate factors in the indirect effects of childhood abuse on state anxiety in adulthood, and analyzed the indirect effects via these factors using a path analysis. Subjects and Methods: Child Abuse and Trauma Scale, Subjective Social Status, Rosenberg Self-Esteem Scale, and State-Trait Anxiety Inventory Form Y questionnaires were administered in a self-report format to 404 adult volunteers from January 2014 to August 2014. In addition, a path analysis was conducted to determine whether subjective social status and self-esteem are associated with the indirect effects of childhood abuse on anxiety symptoms in adulthood. Results: Childhood abuse did not directly affect state anxiety in adulthood, but affected state anxiety via subjective social status and self-esteem. Subjective social status affected state anxiety via self-esteem. This model explained 25.2% of the variation in state anxiety in adult volunteers. Conclusion: The present study demonstrated that childhood abuse affects anxiety in adulthood through subjective social status and self-esteem. Therefore, interventions that enhance subjective social status and self-esteem for adults who experienced childhood abuse may help reduce their anxiety.

2.
Brain Res ; 1818: 148511, 2023 11 01.
Article in English | MEDLINE | ID: mdl-37506965

ABSTRACT

Effective blood coagulation prevents inflammation and neuronal loss after brain injury. 2-Carba-cyclic phosphatidic acid (2ccPA), a biotherapeutic for brain injury, inhibits blood extravasation resulting from blood-brain barrier breakdown. However, the hemostasis mechanism of 2ccPA remains unclear. We determined the effects of 2ccPA-injection on blood coagulation and fibrinolysis using a needle-induced brain injury model. 2ccPA suppressed the expression of platelet degranulation-related genes. Immediately after brain injury, 2ccPA increased CD41+ platelet aggregation around the lesions and promoted fibrin aggregation. Additionally, 2ccPA supported fibrinolysis by upregulating plasminogen activator expression. These results suggest the acute effects of 2ccPA on brain hemostasis.


Subject(s)
Brain Injuries , Fibrinolysis , Humans , Fibrinolysis/physiology , Phosphatidic Acids/pharmacology , Blood Coagulation , Brain Injuries/drug therapy
3.
Neurosci Lett ; 797: 137063, 2023 02 16.
Article in English | MEDLINE | ID: mdl-36634888

ABSTRACT

2-carba-cyclic phosphatidic acid (2ccPA) suppresses microglial and astrocyte inflammation for neuronal survival following traumatic brain injury. However, it remains unknown how 2ccPA regulates microglial activation. In this study, to elucidate the 2ccPA behavior in glial communication, we collected the astrocyte conditioned media (ACM) from primary astrocyte cultures that were treated by lipopolysaccharide (LPS) and 2ccPA and analyzed the alteration of microglial inflammation caused by the ACM treatment. The addition of the ACM derived from LPS- and 2ccPA-double treated astrocytes to microglia decreased the CD86+ pro-inflammatory M1 microglia, which were upregulated with the ACM collected from astrocytes treated by LPS without 2ccPA, while the direct addition of LPS and 2ccPA to microglia failed to decrease the CD86+ microglia to the basal level. We confirmed that the ACM from LPS- and 2ccPA-treated astrocytes increased the ratio of CD206+ anti-inflammatory M2 microglia to total microglia, whereas direct treatment of microglia with LPS and 2ccPA had no effect on the CD206+ microglia ratio, demonstrating the importance of astrocyte intervention in microglial polarization. In addition, we examined whether astrocytes modulate the 2ccPA-regulated proinflammatory cytokine production derived from microglia. The addition of the ACM from LPS- and 2ccPA-treated astrocytes to microglia remarkably canceled the LPS-induced upregulation of IL-1ß, IL-6, and TNF-α secreted from microglia, while the direct addition of LPS and 2ccPA to microglia showed no affect. Therefore, our results indicate that astrocytes mediate the 2ccPA function to shift microglia towards the M2 phenotype by interfering with the polarization of M1 microglia and to suppress cytokine production.


Subject(s)
Anti-Inflammatory Agents , Astrocytes , Cell Communication , Cell Polarity , Inflammation , Microglia , Humans , Anti-Inflammatory Agents/pharmacology , Astrocytes/drug effects , Astrocytes/pathology , Cells, Cultured , Inflammation/metabolism , Inflammation/pathology , Lipopolysaccharides/pharmacology , Microglia/drug effects , Microglia/pathology , Phenotype , Tumor Necrosis Factor-alpha , Cell Communication/drug effects
4.
J Neuroimmunol ; 361: 577749, 2021 12 15.
Article in English | MEDLINE | ID: mdl-34688067

ABSTRACT

We examined the mechanism how 2-carba-cyclic phosphatidic acid (2ccPA), a lipid mediator, regulates neuronal apoptosis in traumatic brain injury (TBI). First, we found 2ccPA suppressed neuronal apoptosis after the injury, and increased the immunoreactivity of tenascin-C (TN-C), an extracellular matrix protein by 2ccPA in the vicinity of the wound region. 2ccPA increased the mRNA expression levels of Tnc in primary cultured astrocytes, and the conditioned medium of 2ccPA-treated astrocytes suppressed the apoptosis of cortical neurons. The neuroprotective effect of TN-C was abolished by knockdown of TN-C. These results indicate that 2ccPA contributes to neuroprotection via TN-C from astrocytes in TBI.


Subject(s)
Astrocytes/metabolism , Brain Injuries, Traumatic/metabolism , Neuroprotective Agents/therapeutic use , Phosphatidic Acids/physiology , Tenascin/metabolism , Animals , Apoptosis/drug effects , Astrocytes/drug effects , Brain Injuries, Traumatic/drug therapy , Cells, Cultured , Cerebral Cortex/cytology , Culture Media, Conditioned/pharmacology , Female , Glial Fibrillary Acidic Protein/biosynthesis , Glial Fibrillary Acidic Protein/genetics , Injections, Intraperitoneal , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred ICR , Neurons/drug effects , Neurons/pathology , Phosphatidic Acids/pharmacology , Phosphatidic Acids/therapeutic use , RNA Interference , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Tenascin/antagonists & inhibitors , Tenascin/genetics , Wounds, Stab/drug therapy , Wounds, Stab/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...